Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

Cancer

Volumn 117, Issue 5, 2011, Pages 992-1000

  Sekeres, Mikkael A ^a   Kantarjian, Hagop ^b   Fenaux, Pierre ^c   Becker, Pamela ^d   Boruchov, Adam ^e   Guerci Bresler, Agnes ^f   Hu, Kuolung ^g   Franklin, Janet ^g   Wang, Yow Ming C ^g   Berger, Dietmar ^g  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c AVICENNE HOSPITAL   (France)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^f Brabois University Hospital Center   (France)

^g AMGEN INC   (United States)

Author keywords

Myelodysplastic syndromes; Romiplostim; Thrombocytopenia; Thrombopoietin receptor activation

Indexed keywords

ROMIPLOSTIM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BRAIN INFARCTION; CLINICAL ARTICLE; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HERPES ZOSTER; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPENIA; PAPULAR RASH; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RISK ASSESSMENT; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; SUBARACHNOID HEMORRHAGE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALGORITHMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RISK FACTORS; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 79952011926     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25545     Document Type: Article

References (16)

1. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705-1714. (Pubitemid 46668530)
2. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of 6 cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542-1551.
3. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
4. Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008;6:1-15.
5. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109:1133-1137. (Pubitemid 46435392)
6. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557. (Pubitemid 40204668)
7. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacytidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903. (Pubitemid 46630737)
8. Gardin C, Fenaux P. Supportive care including growth factors in myelodysplastic syndromes [serial online]. Rev Clin Exp Hematol. 2004;8:E3.
9. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628-638. (Pubitemid 39601552)
10. Nplate (romiplostim) [prescribing information, package insert]. Thousand Oaks, CA: Amgen Inc.; 2008.
11. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. (Pubitemid 27132124)
12. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28:437-444.
13. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425. (Pubitemid 44061337)
14. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000;72:131-133.
15. Raza A, Galili N, Smith S, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009;113:6533-6540.
16. Wng YM, Peez-Ruixo JJ, Xiao J, et al. Pharmacokinetic and pharmacodynamic modeling of romiplostim, a novel thrombopoietic Fc-peptide fusion protein, in healthy subjects: a semimechanistic approach [abstract]. Exp Hematol. 2008;36:S53-S54.